Cargando…
Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
Introduction: Curatively intended chemo-radio-immunotherapy for non-small cell lung cancer (NSCLC) stage III may lead to post-therapeutic pulmonary function (PF) impairment. We hypothesized that the decrease in global PF corresponds to the increase in tissue density in follow-up CTs. Hence, the stud...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139430/ https://www.ncbi.nlm.nih.gov/pubmed/35626183 http://dx.doi.org/10.3390/diagnostics12051027 |
_version_ | 1784714857340207104 |
---|---|
author | Stana, Markus Grambozov, Brane Gaisberger, Christoph Karner, Josef Ruznic, Elvis Berchtold, Johannes Zellinger, Barbara Moosbrugger, Raphaela Studnicka, Michael Fastner, Gerd Sedlmayer, Felix Zehentmayr, Franz |
author_facet | Stana, Markus Grambozov, Brane Gaisberger, Christoph Karner, Josef Ruznic, Elvis Berchtold, Johannes Zellinger, Barbara Moosbrugger, Raphaela Studnicka, Michael Fastner, Gerd Sedlmayer, Felix Zehentmayr, Franz |
author_sort | Stana, Markus |
collection | PubMed |
description | Introduction: Curatively intended chemo-radio-immunotherapy for non-small cell lung cancer (NSCLC) stage III may lead to post-therapeutic pulmonary function (PF) impairment. We hypothesized that the decrease in global PF corresponds to the increase in tissue density in follow-up CTs. Hence, the study aim was to correlate the dynamics in radiographic alterations to carbon monoxide diffusing capacity (DL [Formula: see text]) and FEV [Formula: see text] , which may contribute to a better understanding of radiation-induced lung disease. Methods: Eighty-five patients with NSCLC III were included. All of them received two cycles of platinum-based induction chemotherapy followed by high dose radiation. Thereafter, durvalumab was administered for one year in 63/85 patients (74%). Pulmonary function tests (PFTs) were performed three months and six months after completion of radiotherapy (RT) and compared to baseline. At the same time points, patients underwent diagnostic CT (dCT). These dCTs were matched to the planning CT (pCT) using RayStation(®) Model Based Segmentation and deformable image registration. Differential volumes defined by specific isodoses were generated to correlate them with the PFTs. Results: In general, significant correlations between PFTs and differential volumes were found in the mid-dose range, especially for the volume of the lungs receiving between 65% and 45% of the dose prescribed (V [Formula: see text]) and DL [Formula: see text] ([Formula: see text]). This volume range predicted DL [Formula: see text] after RT (p-value 0.03) as well. In multivariate analysis, DL [Formula: see text] (p-value 0.040) and FEV [Formula: see text] (p-value 0.014) predicted pneumonitis. Conclusions: The current analysis revealed a strong relation between the dynamics of DL [Formula: see text] and CT morphology changes in the mid-dose range, which convincingly indicates the importance of routinely used PFTs in the context of a curative treatment approach. |
format | Online Article Text |
id | pubmed-9139430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91394302022-05-28 Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III Stana, Markus Grambozov, Brane Gaisberger, Christoph Karner, Josef Ruznic, Elvis Berchtold, Johannes Zellinger, Barbara Moosbrugger, Raphaela Studnicka, Michael Fastner, Gerd Sedlmayer, Felix Zehentmayr, Franz Diagnostics (Basel) Article Introduction: Curatively intended chemo-radio-immunotherapy for non-small cell lung cancer (NSCLC) stage III may lead to post-therapeutic pulmonary function (PF) impairment. We hypothesized that the decrease in global PF corresponds to the increase in tissue density in follow-up CTs. Hence, the study aim was to correlate the dynamics in radiographic alterations to carbon monoxide diffusing capacity (DL [Formula: see text]) and FEV [Formula: see text] , which may contribute to a better understanding of radiation-induced lung disease. Methods: Eighty-five patients with NSCLC III were included. All of them received two cycles of platinum-based induction chemotherapy followed by high dose radiation. Thereafter, durvalumab was administered for one year in 63/85 patients (74%). Pulmonary function tests (PFTs) were performed three months and six months after completion of radiotherapy (RT) and compared to baseline. At the same time points, patients underwent diagnostic CT (dCT). These dCTs were matched to the planning CT (pCT) using RayStation(®) Model Based Segmentation and deformable image registration. Differential volumes defined by specific isodoses were generated to correlate them with the PFTs. Results: In general, significant correlations between PFTs and differential volumes were found in the mid-dose range, especially for the volume of the lungs receiving between 65% and 45% of the dose prescribed (V [Formula: see text]) and DL [Formula: see text] ([Formula: see text]). This volume range predicted DL [Formula: see text] after RT (p-value 0.03) as well. In multivariate analysis, DL [Formula: see text] (p-value 0.040) and FEV [Formula: see text] (p-value 0.014) predicted pneumonitis. Conclusions: The current analysis revealed a strong relation between the dynamics of DL [Formula: see text] and CT morphology changes in the mid-dose range, which convincingly indicates the importance of routinely used PFTs in the context of a curative treatment approach. MDPI 2022-04-19 /pmc/articles/PMC9139430/ /pubmed/35626183 http://dx.doi.org/10.3390/diagnostics12051027 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Stana, Markus Grambozov, Brane Gaisberger, Christoph Karner, Josef Ruznic, Elvis Berchtold, Johannes Zellinger, Barbara Moosbrugger, Raphaela Studnicka, Michael Fastner, Gerd Sedlmayer, Felix Zehentmayr, Franz Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III |
title | Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III |
title_full | Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III |
title_fullStr | Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III |
title_full_unstemmed | Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III |
title_short | Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III |
title_sort | carbon monoxide diffusing capacity (dl(co)) correlates with ct morphology after chemo-radio-immunotherapy for non-small cell lung cancer stage iii |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139430/ https://www.ncbi.nlm.nih.gov/pubmed/35626183 http://dx.doi.org/10.3390/diagnostics12051027 |
work_keys_str_mv | AT stanamarkus carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT grambozovbrane carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT gaisbergerchristoph carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT karnerjosef carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT ruznicelvis carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT berchtoldjohannes carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT zellingerbarbara carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT moosbruggerraphaela carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT studnickamichael carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT fastnergerd carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT sedlmayerfelix carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii AT zehentmayrfranz carbonmonoxidediffusingcapacitydlcocorrelateswithctmorphologyafterchemoradioimmunotherapyfornonsmallcelllungcancerstageiii |